<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neuropsychopharmacology</journal-id>
<journal-id journal-id-type="iso-abbrev">Neuropsychopharmacology</journal-id>
<journal-title-group>
<journal-title>Neuropsychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0893-133X</issn>
<issn pub-type="epub">1740-634X</issn>
<publisher>
<publisher-name>Springer International Publishing</publisher-name>
<publisher-loc>Cham</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29520058</article-id>
<article-id pub-id-type="pmc">5983537</article-id>
<article-id pub-id-type="publisher-id">34</article-id>
<article-id pub-id-type="doi">10.1038/s41386-018-0034-8</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Histone deacetylases mediate GABA<sub>A</sub> receptor expression, physiology, and behavioral maladaptations in rat models of alcohol dependence</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-8713-4436</contrib-id>
<name>
<surname>Bohnsack</surname>
<given-names>John Peyton</given-names>
</name>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hughes</surname>
<given-names>Benjamin A.</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>O’Buckley</surname>
<given-names>Todd K.</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Edokpolor</surname>
<given-names>Kamyra</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Besheer</surname>
<given-names>Joyce</given-names>
</name>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4441-956X</contrib-id>
<name>
<surname>Morrow</surname>
<given-names>A. Leslie</given-names>
</name>
<address>
<email>morrow@med.unc.edu</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution>Department of Pharmacology, </institution><institution>University of North Carolina at Chapel Hill, </institution></institution-wrap>Chapel Hill, NC 27599-7178 USA </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution>Bowles Center for Alcohol Studies, </institution><institution>University of North Carolina at Chapel Hill, </institution></institution-wrap>Chapel Hill, NC 27599-7178 USA </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution>Department of Psychiatry, </institution><institution>University of North Carolina at Chapel Hill, </institution></institution-wrap>Chapel Hill, NC 27599-7178 USA </aff>
<aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2175 0319</institution-id><institution-id institution-id-type="GRID">grid.185648.6</institution-id><institution>Present Address: Department of Psychiatry, </institution><institution>University of Illinois at Chicago, </institution></institution-wrap>Chicago, IL 60612 USA </aff>
<aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0941 6502</institution-id><institution-id institution-id-type="GRID">grid.189967.8</institution-id><institution>Present Address: Neuroscience Graduate Program, </institution><institution>Emory University, </institution></institution-wrap>Atlanta, GA 30322 USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>27</day>
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>6</month>
<year>2018</year>
</pub-date>
<volume>43</volume>
<issue>7</issue>
<fpage>1518</fpage>
<lpage>1529</lpage>
<history>
<date date-type="received">
<day>24</day>
<month>10</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>27</day>
<month>11</month>
<year>2017</year>
</date>
<date date-type="accepted">
<day>13</day>
<month>2</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© American College of Neuropsychopharmacology 2018</copyright-statement>
</permissions>
<abstract id="Abs1">
<p id="Par1">Alcohol use disorders are chronic debilitating diseases characterized by severe withdrawal symptoms that contribute to morbidity and relapse. GABA<sub>A</sub> receptor (GABA<sub>A</sub>R) adaptations have long been implicated in the chronic effects of alcohol and contribute to many withdrawal symptoms associated with alcohol dependence. In rodents, GABA<sub>A</sub>R hypofunction results from decreases in <italic>Gabra1</italic> expression, although the underlying mechanism controlling <italic>Gabra1</italic> expression after chronic ethanol exposure is still unknown. We found that chronic ethanol exposure using either ethanol gavage or two-bottle choice voluntary access paradigms decreased <italic>Gabra1</italic> expression and increased <italic>Hdac2</italic> and <italic>Hdac3</italic> expression. Administration of the HDAC inhibitor trichostatin A (TSA) after chronic ethanol exposure prevents the decrease in <italic>Gabra1</italic> expression and function as well as the increase in <italic>Hdac2</italic> and <italic>Hdac3</italic> expression in both the cortex and the medial prefrontal cortex (mPFC). Chronic ethanol exposure and withdrawal, but not acute ethanol exposure or acute withdrawal, cause a selective upregulation of HDAC2 and HDAC3 associated with the <italic>Gabra1</italic> promoter that accompanies a decrease in H3 acetylation of the <italic>Gabra1</italic> promoter and the reduction in GABA<sub>A</sub>R α1 subunit expression. TSA administration prevented each of these molecular events as well as behavioral manifestations of ethanol dependence, including tolerance to zolpidem-induced loss of righting reflex, reduced open-arm time in the elevated plus maze, reduced center-time and locomotor activity in the open-field assay, and TSA reduced voluntary ethanol consumption. The results show how chronic ethanol exposure regulates the highly prominent GABA<sub>A</sub>R α1 subunit by an epigenetic mechanism that represents a potential treatment modality for alcohol dependence.</p>
</abstract>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© American College of Neuropsychopharmacology 2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
</article>
</pmc-articleset>